American Diabetes Association. 6. Glycemic goals and hypoglycemia: standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement_1):S111–25. https://doi.org/10.2337/dc24-S006.

Article  Google Scholar 

HEDIS MY 2023 Volume 2 (Epub). NCQA; https://store.ncqa.org/hedis-my-2023-volume-2-epub.html. Accessed Mar 2023

Fang M, Wang D, Coresh J, Selvin E. Trends in diabetes treatment and control in US adults, 1999–2018. N Engl J Med. 2021;384(23):2219–28. https://doi.org/10.1056/NEJMsa2032271.

Article  PubMed  PubMed Central  Google Scholar 

American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024.". Diabetes Care. 2024;47(Supplement_1):S158–78. https://doi.org/10.2337/dc24-S009.

Article  Google Scholar 

Schiavon M, Visentin R, Göbel B, Riz M, Cobelli C, Klabunde T, Dalla MC. Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide. Diabetes Obes Metab. 2021;23(8):1795–805. https://doi.org/10.1111/dom.14394.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nachawi N, Rao PP, Makin V. The role of GLP-1 receptor agonists in managing type 2 diabetes. Cleve Clin J Med. 2022;89(8):457–64. https://doi.org/10.3949/ccjm.89a.21110.

Article  PubMed  Google Scholar 

Weiss T, Yang L, Carr RD, Pal S, Sawhney B, Boggs R, Rajpathak S, Iglay K. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. BMJ Open Diabetes Res Care. 2022;10(1): e002517. https://doi.org/10.1136/bmjdrc-2021-002517.

Article  PubMed  PubMed Central  Google Scholar 

Chavda VP, Ajabiya J, Teli D, et al. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022;27(13):4315. https://doi.org/10.3390/molecules27134315.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, Marx N, Brosius FC, Mustafa RA, Agarwal A, Zou X. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;6:381. https://doi.org/10.1136/bmj-2022-074068.

Article  Google Scholar 

Jung H, Tittel SR, Schloot NC, Heitmann E, Otto T, Lebrec J, Pavel M, Lanzinger S. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: a retrospective analysis of the diabetes prospective follow-up registry. Diabetes Obes Metab. 2023;25(7):1813–22. https://doi.org/10.1111/dom.15038.

Article  PubMed  CAS  Google Scholar 

Do D, Lee T, Peasah SK, Good CB, Inneh A, Patel U. GLP-1 receptor agonist discontinuation among patients with obesity and/or type 2 diabetes. JAMA Netw Open. 2024;7(5):e2413172. https://doi.org/10.1001/jamanetworkopen.2024.13172.

Article  PubMed  PubMed Central  Google Scholar 

American Diabetes Association. 7. Diabetes technology: standards of care in diabetes—2024. Diabetes Care. 2024;47(Supplement_1):S126–44. https://doi.org/10.2337/dc24-S007.

Article  Google Scholar 

Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Diabetes Ther. 2017;8:573–86. https://doi.org/10.1007/s13300-017-0255-6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167:365–74. https://doi.org/10.7326/M16-2855.

Article  PubMed  Google Scholar 

Ruedy KJ, Parkin CG, Riddlesworth TD, Graham C, for the DIAMOND Study Group. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11(6):1138–46. https://doi.org/10.1177/1932296817704445.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fokkert M, van Dijk P, Edens M, et al. Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4). BMJ Open Diabetes Res Care. 2019;7(1): e000809. https://doi.org/10.1136/bmjdrc-2019-000809.

Article  PubMed  PubMed Central  Google Scholar 

Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. Diabetes Care. 2017;40(4):538–45. https://doi.org/10.2337/dc16-2482.

Article  PubMed  PubMed Central  Google Scholar 

Lind M, Polonsky W, Hirsch IB. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317(4):379–87. https://doi.org/10.1001/jama.2016.19976.

Article  PubMed  CAS  Google Scholar 

Oskarsson P, Antuna R, Geelhoed-Duijvestijn P, et al. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial. Diabetologia. 2018;61(3):539–50. https://doi.org/10.1007/s00125-017-4527-5.

Article  PubMed  CAS  Google Scholar 

Heinemann L, Guido Freckmann G, Gabriele Faber-Heinemann G, et al. Benefits of continuous glucose monitoring use in adults with type 1 diabetes and impaired hypoglycaemia awareness and/or severe hypoglycaemia treated with multiple daily insulin injections: Results of the multicentre, randomised controlled HypoDE study. Lancet. 2018;391(10128):1367–77. https://doi.org/10.1016/S0140-6736(18)30297-6.

Article  PubMed  CAS  Google Scholar 

Charleer S, De Block C, Van Huffel L, et al. Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study. Diabetes Care. 2020;43(2):389–97. https://doi.org/10.2337/dc19-1610.

Article  PubMed  Google Scholar 

van Beers CA, DeVries JH, Kleijer SJ, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016;4(11):893–902. https://doi.org/10.1016/S2213-8587(16)30193-0.

Article  PubMed  Google Scholar 

Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254–63. https://doi.org/10.1016/S0140-6736(16)31535-5.

Article  PubMed  Google Scholar 

Leelarathna L, Evans ML, Neupane S, Rayman G, Lumley S, Cranston I, Narendran P, Barnard-Kelly K, Sutton CJ, Elliott RA, Taxiarchi VP. Intermittently scanned continuous glucose monitoring for type 1 diabetes. N Engl J Med. 2022;387(16):1477–87. https://doi.org/10.1056/NEJMoa2205650.

Article  PubMed  CAS  Google Scholar 

Wright EE, Kerr MSD, Reyes IJ, Nabutovsky Y, Miller M. Use of flash continuous glucose monitoring is associated with A1C reduction in people with type 2 diabetes treated with basal insulin or non-insulin therapy. Diabetes Spectr. 2021;34(2):184–9. https://doi.org/10.2337/ds20-0069.

Article  PubMed  PubMed Central  Google Scholar 

Aronson R, Brown RE, Chu L, Bajaj HS, Khandwala H, Abitbol A, Malakieh N, Goldenberg R. IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): a randomized controlled trial. Diabetes Obes Metab. 2023;25(4):1024–31. https://doi.org/10.1111/dom.14949.

Article  PubMed  CAS  Google Scholar 

Wada E, Onoue T, Kobayashi T, Handa T, Hayase A, Ito M, Furukawa M, Okuji T, Okada N, Iwama S, Sugiyama M. Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care. 2020;8(1): e001115. https://doi.org/10.1136/bmjdrc-2019-001115.

Article  PubMed  PubMed Central  Google Scholar 

Miller D, Kerr MSD, Roberts GJ, et al. Flash CGM associated with event reduction in nonintensive diabetes therapy. Am J Manag Care. 2021;27(11):e372–7. https://doi.org/10.37765/ajmc.2021.88780.

Article  PubMed